RxDoctor Payments DataLook up a doctor →

Daniel Meline, MD

Gastroenterology · Scottsdale, AZNPI 1982714960

Payments from drug & device makers

$794,831in general payments, 2019–2025

Across 1,180 payments — averaging $673.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Nestle Healthcare Nutrition Inc.$275K
  • Aimmune Therapeutics, Inc.$209K
  • Phathom Pharmaceuticals, Inc.$167K
  • AbbVie$134K
  • Ironwood Pharmaceuticals, Inc$8K
  • Sanofi$534
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$2500%
  • Speaking & faculty fees$704,10589%
  • Travel & lodging$71,4359%
  • Food & beverage$18,9072%
  • Education$70%
  • Other$1270%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$794,831 in reported general payments places this provider in the 95th percentile of 355 gastroenterology providers in Arizona.

See all gastroenterology providers in Arizona

Medicare billing

Part B allowed, 2024
$199,611
Medicare patients
681
Services billed
1,729

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VoqueznaVonoprazan Fumarate41$35,491
SutabSod Sulf/Pot Chloride/Mag Sulf206$33,418
LinzessLinaclotide25$32,050
Mesalamine12$10,768
Dexlansoprazole DrDexlansoprazole17$6,977
Pantoprazole Sodium325$4,537
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates25$1,518
Esomeprazole Magnesium13$565
Budesonide DrBudesonide14$532
Omeprazole54$329
Lansoprazole17$316
Azathioprine12$271
Famotidine14$133

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Phathom Pharmaceuticals, Inc.Voquezna$167,357$35,49141 claims
Braintree Laboratories, Inc.Sutab$13$33,418206 claims
AbbVieLinzess$133,925$32,05025 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 355 gastroenterology providers in Arizona.

Other gastroenterology in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →